(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
Animal Model: |
KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras/p53] |
Dosage: |
30, 60, or 120 mg/kg |
Administration: |
Oral gavage; 60 days |
Result: |
Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
|
Animal Model: |
Male rats |
Dosage: |
30, 100 mg/kg (Pharmacokinetic Analysis) |
Administration: |
Oral gavage twice a day; on days 1 and 5 |
Result: |
Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
|